Quest Partners LLC Takes $166,000 Position in Repligen Co. (NASDAQ:RGEN)

Quest Partners LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,118 shares of the biotechnology company’s stock, valued at approximately $166,000.

Other institutional investors and hedge funds have also modified their holdings of the company. O Shaughnessy Asset Management LLC boosted its holdings in Repligen by 6.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 125 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in Repligen by 14.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 6,872 shares of the biotechnology company’s stock worth $1,264,000 after purchasing an additional 851 shares in the last quarter. Bayesian Capital Management LP boosted its holdings in Repligen by 141.0% in the first quarter. Bayesian Capital Management LP now owns 2,800 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 1,638 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its holdings in Repligen by 12.6% in the first quarter. B. Riley Wealth Advisors Inc. now owns 1,450 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 162 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on RGEN shares. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Price Performance

Shares of RGEN stock opened at $149.99 on Thursday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a market capitalization of $8.40 billion, a P/E ratio of -396.58, a P/E/G ratio of 4.40 and a beta of 0.96. The stock has a 50 day moving average of $140.58 and a two-hundred day moving average of $142.84. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the company posted $0.23 earnings per share. Repligen’s revenue was up 9.7% on a year-over-year basis. As a group, equities analysts expect that Repligen Co. will post 1.52 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.